480 filings
Page 9 of 24
8-K
ACST
Acasti Pharma Inc.
11 Sep 20
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
7:00am
DEFA14A
ACST
Acasti Pharma Inc.
11 Sep 20
Additional proxy soliciting materials
7:00am
DEF 14A
ACST
Acasti Pharma Inc.
9 Sep 20
Definitive proxy
4:00pm
8-K
ACST
Acasti Pharma Inc.
31 Aug 20
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
4:05pm
10-Q
2021 Q1
ACST
Acasti Pharma Inc.
13 Aug 20
Quarterly report
8:30am
8-K
ACST
Acasti Pharma Inc.
13 Aug 20
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
8:30am
PRE 14A
ACST
Acasti Pharma Inc.
10 Aug 20
Preliminary proxy
12:00am
8-K
ACST
Acasti Pharma Inc.
31 Jul 20
Regulation FD Disclosure
4:05pm
EFFECT
ACST
Acasti Pharma Inc.
8 Jul 20
Notice of effectiveness
12:16am
424B5
ACST
Acasti Pharma Inc.
7 Jul 20
Prospectus supplement for primary offering
4:32pm
CORRESP
ACST
Acasti Pharma Inc.
6 Jul 20
Correspondence with SEC
12:00am
UPLOAD
ACST
Acasti Pharma Inc.
2 Jul 20
Letter from SEC
12:00am
8-K
ACST
Acasti Pharma Inc.
30 Jun 20
Entry into a Material Definitive Agreement
9:01am
10-K
2020 FY
ACST
Acasti Pharma Inc.
29 Jun 20
Annual report
4:02pm
8-K
ACST
Acasti Pharma Inc.
29 Jun 20
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
12:50pm
S-3
ACST
Acasti Pharma Inc.
29 Jun 20
Shelf registration
12:00am
8-K
ACST
Acasti Pharma Inc.
19 Jun 20
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
9:09am
8-K
ACST
Acasti Pharma Inc.
30 Apr 20
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
4:22pm
8-K
ACST
Acasti Pharma Inc.
20 Apr 20
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
4:05pm
8-K
ACST
Acasti Pharma Inc.
1 Apr 20
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
5:12pm